YI — 111, Inc.

Summary of YI (Q4 2024) Earnings Call

1. Key Financial Results and Metrics:

• Q4 2024 Performance:

  • Total net revenues: RMB 3.8 billion, down 6.3% year-over-year.
  • Gross segment profit: RMB 202.5 million, down 5.5%.
  • Total operating expenses decreased by 50.1% to RMB 209.8 million, representing 5.5% of revenues (down from 10.2%).
  • Non-GAAP loss from operations: RMB 2.3 million, a 95.8% improvement from RMB 55.2 million in Q4 2023.
  • Non-GAAP net loss attributable to ordinary shareholders: RMB 14.8 million, down 74.9% from RMB 59 million.

• Full Year 2024 Performance:

  • Total net revenues: RMB 14.4 billion, down 3.7% year-over-year.
  • Gross segment profit: RMB 829.2 million, down 2.3%.
  • Income from operations: RMB 2.1 million, a turnaround from a loss of RMB 351 million in 2023.
  • First-ever annual positive operating cash flow: RMB 263 million.

2. Strategic Updates and Business Highlights:

• Achieved operational profitability and positive operating cash flow for the first time, attributed to enhanced operational efficiency and cost management.
• Significant reduction in operating expenses across various categories: selling expenses (2% of revenues), general and administrative expenses (0.5%), and technology expenses (0.4%).
• Expansion of digital capabilities and AI integration, enhancing inventory management and customer engagement.
• Launched the Kunpeng Network to streamline logistics and reduce costs, expanding last-mile delivery coverage and fulfillment centers.
• Recognition as a leading healthcare and pharmaceutical company for investment and innovation in digital transformation.

3. Forward Guidance and Outlook:

• The company remains optimistic about long-term growth in China's healthcare market, driven by structural trends such as an aging population and ongoing healthcare reforms.
• Plans to expand fulfillment centers and enhance supply chain capabilities, targeting at least 15 new centers in 2025.
• Continued investment in AI and digital technologies to drive operational efficiency and customer engagement.
• Management expects sustained profitability and positive cash flow generation moving forward.

4. Bad News, Challenges, or Points of Concern:

• The broader healthcare sector faces macroeconomic pressures, with a reported 3.6% growth in per capita healthcare expenditure, a decline from previous years.
• Retail pharmacy sales in China decreased by 2.2% in 2024, intensifying competition and impacting revenues.
• Ongoing healthcare reforms may present short-term challenges as the industry adapts to new policies and regulatory frameworks.
• Potential risks related to repayment obligations to investors, with ongoing negotiations to reschedule repayments.

5. Notable Q&A Insights:

• Management highlighted that despite adverse macro conditions, they achieved significant milestones in operational efficiency and profitability.
• Gross margin improvements were driven by a mix of low and high-margin products, strategic outsourcing, and decentralized inventory management.
• Future expense control will focus on leveraging AI and technology for continuous optimization.
• The company plans to expand partnerships with pharmaceutical companies and pharmacies to enhance drug promotion and accessibility through digital platforms.
• Management emphasized the importance of AI in driving future growth and operational efficiency, with ongoing investments in AI technologies.

Overall, YI demonstrated resilience in a challenging market, achieving key financial milestones while positioning itself for future growth through strategic investments in technology and supply chain enhancements.